[2007年翱翔艺术培训中心招生信息] [2007年翱翔艺术培训中心收费标准] [高考] [成人高考] [业余爱好] [ 报名须知]

Adidas Los Angeles Nmd

probability of ultimately meeting the study endpoints, but given that the initial study enrollment was about three months ahead of schedule, we still anticipate having top line results by the end of the first quarter of 2015. In addition, the expanded sample size will provide an adequate number of subjects to complete the required long Adidas Los Angeles Trainers Black

Adidas Los Angeles Nmd

BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy

to maintain the Adidas Neo Lite Racer White

term safety study that will be part of our NDA package. Also part of the NDA will be a second pivotal trial that we anticipate starting in early 2015.""The outcome of the interim analysis is significant because it utilized actual study data to make a sample size adjustment to maintain the probability of a successful outcome," said Dr. Mark A. Sirgo, President and Chief Executive Officer. "Based on this information we will continue to progress other aspects of the clinical development program necessary for the NDA."BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.BDSI development strategy focuses on utilization of the FDA 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.BDSI particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.BDSI headquarters is located inRaleigh, North Carolina.Cautionary Note on Forward Looking StatementsThis press release and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company management and are subject to significant risks and uncertainties, including those detailed in the Company filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company Phase 3 pivotal and safety studies of Clonidine Topical Gel) may differ significantly from those set forth in the forward looking statements. These forward looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company control). The Company undertakes no obligation to publicly update any forward looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.BDSIand BEMAare registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences logo and BUNAVAIL are trademarks owned by BioDelivery Sciences International, Inc. ONSOLISis a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL is a trademark owned by Meda Pharma GmbH Co. KG. PAINKYLis a trademark owned by TTY Biopharm. All other trademarks and tradenames are owned by their respective owners.

Adidas Los Angeles Nmd

Adidas Los Angeles Nmd

Adidas Los Angeles Nmd

Adidas Los Angeles Nmd

Adidas Los Angeles Nmd

Adidas Los Angeles Nmd

Information contained on this page is provided by an independent third party content provider. WorldNow and this Station make no warranties or representations in connection therewith. 6, 2014 /PRNewswire/ BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that it has completed a pre specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN).The interim analysis was performed on data from the first 50% of patients who completed the study. The purpose of the interim analysis was to allow for a sample size adjustment if necessary to maintain appropriate statistical power to detect a treatment effect between Clonidine Topical Gel and placebo.BDSI views the outcome of the analysis as very encouraging. As a result of the interim analysis, a total of approximately 80 additional patients will be added to the ongoing trial in an effort to maintain 90% percent power to detect a statistically significant difference between Clonidine Topical Gel and placebo. The analysis was executed by an independent biostatistician."We are encouraged by the outcome of the interim analysis," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI. Adidas Los Angeles Nmd "The additional patients not only allow us Adidas Neo Cloudfoam All Black

Adidas Los Angeles Nmd

Adidas Los Angeles Nmd

Adidas Los Angeles Nmd

Adidas Los Angeles Nmd

Nike Green Joggers
Nike Mens Shorts Size Chart
Adidas Neo Vl Court

Adidas Primeknit Tubular Instinct

Nike Men T Shirts
Adidas Neo Lite Racer Red

Adidas Los Angeles Mens Shoes

Nike Winter Coat Womens
Adidas Neo Lite Racer Leopard

Nike Red Shorts
Adidas Los Angeles Night Sky

Adidas Los Angeles Dots

Adidas Originals Womens Black

Adidas Los Angeles Mesh

Adidas Primeknit Runner

Home / Adidas Los Angeles Nmd
本站简介 | 翱翔版权所有 | 招聘信息 | BBS论坛 | 网站留言
联系管理员zwtzxb@126.com QQ:147120823
 翱翔艺术培训中心版权所有
Copyright@2007 www.axyishu.com Co,LTD.
All worldwide   rights reserved.
联系电话:010-65816007 13810717616